ZCA
GSK icon

Zeke Capital Advisors’s GSK GSK Stock Holding History

Zeke Capital Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,329
Closed -$563K – 506
2022
Q1 		$563K Buy
10,329
+1,579
+18% +$85.8K 0.03% 210
2021
Q4 		$482K Buy
8,750
+904
+12% +$47K 0.03% 157
2021
Q3 		$375K Sell
7,846
-400
-5% -$20.1K 0.02% 181
2021
Q2 		$410K Sell
8,246
-208
-2% -$9.99K 0.03% 169
2021
Q1 		$377K Buy
8,454
+116
+1% +$5.26K 0.03% 166
2020
Q4 		$384K Sell
8,338
-2,172
-21% -$99.8K 0.03% 156
2020
Q3 		$494K Sell
10,510
-924
-8% -$46.3K 0.06% 109
2020
Q2 		$583K Sell
11,434
-74
-0.6% -$3.8K 0.11% 90
2020
Q1 		$545K Sell
11,508
-35,530
-76% -$1.9M 0.15% 81
2019
Q4 		$2.76M Sell
47,038
-5,357
-10% -$298K 0.23% 86
2019
Q3 		$2.79M Sell
52,395
-158
-0.3% -$8.13K 0.25% 83
2019
Q2 		$2.63M Buy
52,553
+1,260
+2% +$63.2K 0.25% 80
2019
Q1 		$2.68M Buy
51,293
+13,961
+37% +$698K 0.25% 81
2018
Q4 		$1.78M Buy
+37,332
New +$1.84M 0.17% 98

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Zeke Capital Advisors's GSK Position: Q2 2022 in Review

Zeke Capital Advisors sold out of GSK (GSK) in Q2 2022, closing a stake of 10,329 shares — an estimated $563K sold.

Zeke Capital Advisors first reported a position in GSK in Q4 2018 and held it in 14 quarters. The position peaked at $2.79M in Q3 2019. 900 funds tracked by Wall St. Rank hold GSK as of Q2 2022.

  • Zeke Capital Advisors reported no remaining GSK position as of Q2 2022 after selling out during the quarter.
  • Zeke Capital Advisors sold 10,329 GSK shares in Q2 2022, an estimated $563K.
  • Zeke Capital Advisors first reported a position in GSK in Q4 2018 and held it in 14 quarters.
  • Zeke Capital Advisors's GSK position peaked at $2.79M in Q3 2019.
  • 900 funds tracked by Wall St. Rank held GSK as of Q2 2022.

Based on Zeke Capital Advisors's 13F filing for Q2 2022, filed 9 Aug 2022.